Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring Acute Myocardial Infarction, Heart Attack, Cardiovascular Disease, Stem cells, Congestive Heart Failure, Heart Attack Repair
Eligibility Criteria
Inclusion Criteria: Male or female between 21 and 85 years old First heart attack within 1 to 10 days Exclusion Criteria: Positive for HIV 1 and 2 Previous heart attack Pacemaker or other device Pregnant or breastfeeding Allergic to cow or pig derived products Previous bone marrow transplant Involved in another clinical trial within the past 30 days Alcohol or recreational drug abuse within the past 6 months Hepatitis Positive Major surgical procedure or major trauma within the past 14 days Body weight greater than 300 pounds Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)
Sites / Locations
- Arizona Heart Institute
- University of California - San Diego; Thornton
- Washington Hospital Center
- Rush University Medical Center
- The Care Group
- Jewish Hospital
- Johns Hopkins University
- Washington Adventist
- Minneapolis Heart Institute
- Columbia Presbyterian Hospital
- University of Rochester - Strong Memorial
- University of Oklahoma Health Sciences Center
- University of Pennsylvania Medical Center
- Austin Heart Institute
- Texas Medical School
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Provacel: Cohort 1
Provacel: Cohort 2
Provacel: Cohort 3
Provacel: Cohort 4
Placebo
ex vivo cultured adult mesenchymal stem cells
ex vivo cultured adult mesenchymal stem cells
ex vivo cultured adult mesenchymal stem cells
ex vivo cultured adult mesenchymal stem cells
ex vivo cultured adult mesenchymal stem cells